



PsA Forum

Tailored approaches to psoriatic arthritis

An Amgen-sponsored forum

3–4 and 9–10 March 2021

Agenda

KEY DETAILS



Dates: March 3–4 and 9–10, 2021, at 18:00 CET



Format: Virtual hub and spoke meeting containing both live and pre-recorded sessions



Hub location: Virtual



Spoke locations: Multiple sites across Europe



Audience: Rheumatologists and dermatologists with an interest in psoriatic arthritis (PsA)

FORUM LEARNING OBJECTIVES

By the end of this meeting, attendees should be able to:

1. Recognize the heterogeneous nature of PsA, and describe how disease manifestations and comorbidities can contribute to a complex, individual burden of disease
2. Describe how patients with moderate/oligoarticular PsA (oPsA) may have limited joint involvement but still exhibit a substantial burden of disease, which can impact their quality of life (QoL)
3. Highlight the importance of accurate assessment of disease severity in patients with moderate PsA/oPsA to enable early clinical intervention and appropriate clinical decision-making
4. Outline the need for a tailored approach to the management and treatment of patients with PsA, where shared decision-making between patients and healthcare professionals (HCPs) ensures that treatment decisions and goals are individualized and patient focused

FACULTY

Chair: **Professor Philip Mease,**
*Swedish Medical Center/Providence St. Joseph Health and
University of Washington, Seattle, WA, USA*

Speakers: **Associate Professor Dr Laura Coates,**
Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Associate Professor Dr Pedro Herranz,
La Paz University Hospital, Madrid, Spain
Professor Georg Schett
University of Erlangen-Nuremberg, Erlangen, Germany
Associate Professor Dr Carlo Selmi,
Humanitas University, Milan, Italy

AGENDA OUTLINE

Day 1

Time	Session	Speaker/facilitator
18:00	Welcome and introduction to the PsA Forum	Philip Mease
18:05	Who are we looking at? Defining the patient with symptoms of moderate/oligoarticular PsA	Philip Mease
18:35	Discussion and activity within spokes	<i>Breakout room leads</i>
18:50	Feedback to main hub and Q&A	Philip Mease
19:15	Interactive quiz	Carlo Selmi
19:30	Summary and close	Philip Mease

Day 2

Time	Session	Speaker/facilitator
18:00	Welcome and introduction to Day 2	Philip Mease
18:05	Race against time: The importance of early identification and treatment of PsA	Laura Coates
18:35	Tailoring our approach: The right treatment for the right person at the right time	Carlo Selmi
19:05	Faculty discussion	All
19:20	Summary and close	Philip Mease

Day 3

Time	Session	Speaker/facilitator
18:00	Welcome and introduction to Day 3	Philip Mease
18:05	Joint thinking: The need for combined care for patients with PsA	Pedro Herranz
18:35	Workshop: Journey of a patient with moderate/oligoarticular PsA: The need for a multidisciplinary approach	<i>Breakout room leads</i>
19:30	Feedback to main hub and Q&A	Philip Mease Pedro Herranz
20:00	Summary and close	Philip Mease

Day 4

Time	Session	Speaker/facilitator
18:00	Welcome and introduction to Day 4	Philip Mease
18:05	What next? Improving outcomes for our patients with moderate/oligoarticular PsA	Georg Schett
18:35	Country-specific approaches to PsA: How can we do things differently and improve patient care?	Georg Schett Laura Coates Carlo Selmi
19:05	Panel discussion and Q&A	All
19:35	Summary and close of the PsA Forum	Philip Mease